400P Targeting immuno-metabolic pathways to overcome resistance to immune-check point inhibitors in obesity-associated breast cancer

Immune checkpoint inhibition (ICI) has improved clinical outcomes in breast cancer (BC), yet it often demonstrates variable response and resistance. New strategies are critically needed, given the rising prevalence of obesity in patients with triple-negative BC (TNBC). Obesity-driven adipose tissue dysfunction and systemic inflammation are known to promote tumour growth. Our previous research showed that body composition and crown-like structures (CLS) are associated with attenuated anti-tumour immune responses and poor survival in BC patients.